Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of KN1102 in Relapsed/Refractory Multiple Myeloma
NCT06379451Phase 1Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Aptiganel in multiple myeloma (MM) (3 arms), sponsored by Changzhou Second People's Hospital. Primary endpoints: Incidence of Dose Limiting Toxicity at 52 weeks and Treatment Emergent Adverse Events at 52 weeks. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
Aptiganel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06379451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06379451.